Advertisement
Advertisement

NAMS

NAMS logo

NewAmsterdam Pharma Company N.V. Ordinary Shares

34.34
USD
Sponsored
+2.28
+7.11%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

34.33

-0.01
-0.03%

NAMS Earnings Reports

Positive Surprise Ratio

NAMS beat 5 of 9 last estimates.

56%

Next Report

Date of Next Report
Mar 04, 2026
Estimate for Q4 25 (Revenue/ EPS)
$5.46M
/
-$0.38
Implied change from Q3 25 (Revenue/ EPS)
+1470.37%
/
-37.70%
Implied change from Q4 24 (Revenue/ EPS)
-57.21%
/
-59.14%

NewAmsterdam Pharma Company N.V. Ordinary Shares earnings per share and revenue

On Nov 05, 2025, NAMS reported earnings of -0.61 USD per share (EPS) for Q3 25, missing the estimate of -0.40 USD, resulting in a -50.95% surprise. Revenue reached 348.00 thousand, compared to an expected 5.39 million, with a -93.55% difference. The market reacted with a +4.37% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 5.46 million USD, implying an decrease of -37.70% EPS, and increase of 1470.37% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, NewAmsterdam Pharma Company N.V. Ordinary Shares reported EPS of -$0.61, missing estimates by -50.95%, and revenue of $348.00K, -93.55% below expectations.
The stock price moved up 4.37%, changed from $36.53 before the earnings release to $38.13 the day after.
The next earning report is scheduled for Mar 04, 2026.
Based on 16 analysts, NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to report EPS of -$0.38 and revenue of $5.46M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement